Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 601–700 of 1,000
Effets secondaires métaboliques de la rispéridone dans les schizophrénies à début précoce
Goëb, J.-L., Marco, S., Duhamel, A., Kechid, G., Bordet, R., Thomas, P., Delion, P., & Jardri, R. (2009) · L Encéphale · doi:10.1016/j.encep.2009.10.008 · Cited by 31
Garg, P., Lillystone, D., Dossetor, D. R., Kefford, C., & Chong, S. (2014) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2014/8243.4527 · Cited by 43
“, perseveration, obsessions, compulsions, and stereotypic movements), mood lability, irritability, anxiety, hyperactivity, inattention, destructive and disruptive patterns [70-74].”
BackgroundGerhard, T., Chavez, B., Olfson, M., & Crystal, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a20c8a · Cited by 31
Wongpakaran, R., Suansanae, T., Tan‐Khum, T., Kraivichian, C., Ongarjsakulman, R., & Suthisisang, C. C. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12518 · Cited by 33
Maddox, B. B., Cleary, P., Kuschner, E. S., Miller, J. S., Armour, A. C., Guy, L., Kenworthy, L. E., Schultz, R. T., & Yerys, B. E. (2017) · Autism · doi:10.1177/1362361317712651 · Cited by 39
Wink, L. K., Adams, R. E., Horn, P. S., Tessier, C. R., Bantel, A. P., Hong, M. P., Shaffer, R. C., Pedapati, E. V., & Erickson, C. A. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3562-5 · Cited by 36
Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review
Iasevoli, F., Barone, A., Buonaguro, E. F., Vellucci, L., & de Bartolomeis, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1820985 · Cited by 31
Evidence-Based Practices in Autism: Where We Are Now and Where We Need to Go
Volkmar, F. R., Reichow, B., & Doehring, P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6975-0_14 · Cited by 34
Self-citationErickson, C. A., Wink, L. K., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., Patrick, V. B., & McDougle, C. J. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1943-3 · Cited by 32
Self-citationDouglas, J. F., Sanders, K. B., Benneyworth, M. H., Smith, J. L., DeJean, V. M., McGrew, S. G., & Veenstra-VanderWeele, J. M. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1661-2 · Cited by 30
“…controlled trials have provided strong evidence for the efficacy of two atypical antipsychotic medications, resulting in FDA approval of risperidone and aripiprazole for the treatment of irritability/ agitation in autistic disorder (McCracken et al. 2002; Owen et al. 2009; Marcus et al. 2009).”
BackgroundIntellectual Disabilities and Mental Health: United States–Based Research
Charlot, L., & Beasley, J. B. (2013) · Journal of Mental Health Research in Intellectual Disabilities · doi:10.1080/19315864.2012.715724 · Cited by 38
Genetic dissection of intermale aggressive behavior in BALB/cJ and A/J mice
Dow, H. C., Kreibich, A. S., Kaercher, K. A., Sankoorikal, G. M. V., Pauley, E. D., Lohoff, F. W., Ferraro, T. N., Li, H., & Brodkin, E. S. (2010) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2010.00640.x · Cited by 33
“…al. 2004; Ducottet & Belzung 2005; Dulawa et al. 2004; Fairless et al. 2008; Guillot & Chapouthier 1996; Jensen et al. 2007; Jones & Brain 1987; Kessler et al. 1977; McCracken et al. 2002; Mineur et al. 2003; Moy et al. 2007; Panksepp et al. 2007; Sankoorikal et al. 2006; Southwick & Clark 1968).”
Anagnostou, E. A., & Hansen, R. L. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834cba3e · Cited by 39
Multiple Antipsychotic Medication Use in Autism Spectrum Disorder
Wink, L. K., Pedapati, E. V., Horn, P. S., McDougle, C. J., & Erickson, C. A. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0123 · Cited by 30
Self-citationReview of interventions for the management of anxiety symptoms in children with ASD
Delli, C. K. S., Polychronopoulou, S. A., Kolaitis, G. A., & Antoniou, A. S. G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.10.023 · Cited by 30
Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study
Marrus, N., Underwood-Riordan, H., Randall, F., Zhang, Y., & Constantino, J. N. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0055 · Cited by 29
Masi, A., Lampit, A., DeMayo, M. M., Glozier, N., Hickie, I. B., & Guastella, A. J. (2017) · Psychological Medicine · doi:10.1017/s0033291716003457 · Cited by 45
“…the safety and efficacy of risperidone in children with autism and serious behaviouural problems have been thoroughly investigated and reported (Arnold et al. 2010); however, this analysis occurred as exploratory investigations after the original study was reported (McCracken et al. 2002).”
ResultTobiasova, Z., van der Lingen, K. H. B., Scahill, L., Leckman, J. F., Zhang, Y., Chae, W., McCracken, J. T., McDougle, C. J., Vitiello, B., Tierney, E., et al. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0134 · Cited by 29
“Forty subjects were treated with risperidone (32 boys, 8 girls, mean age 8.3 – 2.7 years, range 5.2– 16.9 years) and 37 subjects received placebo (29 boys, 8 girls, mean age 9 – 2.5 years, range 5.5–14.8 years) (McCracken et al. 2002).”
BackgroundMethodInfluentialSelf-citationTolerability and safety profile of risperidone in a sample of children and adolescents
Margari, L., Matera, E., Craig, F., Petruzzelli, M. G., Palmieri, V. O., Pastore, A., & Margari, F. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328362497b · Cited by 31
Tierney, E., Aman, M. G., Stout, D., Pappas, K., Arnold, L. E., Vitiello, B., Scahill, L. D., McDougle, C. J., McCracken, J. T., Wheeler, C. S., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0604-z · Cited by 34
Self-citationAnnamneedi, A., Gora, C., Dudas, A., Leray, X., Bozon, V., Crépieux, P., & Pellissier, L. P. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16216 · Cited by 33
“Second, the identification of robust therapeutic targets and the development of potent drugs should thwart the placebo effect.”
Devine, D. P. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3279-2 · Cited by 41
“…side-effect issues with these drugs (Aman et al. 2005), they have been found to have beneficial impacts on global measures of challenging behaviours, including self-injury (McCracken et al. 2002; Canitano 2005; Marcus et al. 2009; Owen et al. 2009; Stigler et al. 2010; Stigler et al. 2012).”
BackgroundKirino, E. (2014) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s8304 · Cited by 31
Rawal, P. H., Lyons, J. S., MacIntyre, J. C., & Hunter, J. C. (2004) · The Journal of Behavioral Health Services & Research · doi:10.1007/bf02287380 · Cited by 33
Initial severity and efficacy of risperidone in autism: Results from the RUPP trial
Levine, S. Z., Kodesh, A., Goldberg, Y., Reichenberg, A., Furukawa, T. A., Kolevzon, A., & Leucht, S. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2015.11.004 · Cited by 35
“The study design [16] and results [15] have been reported.”
BackgroundResultInfluentialLewis, A. S., van Schalkwyk, G. I., Lopez, M. O., Volkmar, F. R., Picciotto, M. R., & Sukhodolsky, D. G. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3536-7 · Cited by 32
“Behavioral treatments are typically considered to be the first-line intervention for this clinical problem (Matson 2009), although a large number of trials support the utility of atypical antipsychotic medications (McCracken et al. 2002; McDougle et al. 2005; Potenza et al. 1999; van Schalkwyk et al. 2017).”
BackgroundSelf-citationEleven Years of Clozapine Experience in Autism Spectrum Disorder: Efficacy and Tolerance
Rothärmel, M., Szymoniak, F., Pollet, C., Beherec, L., Quesada, P., Leclerc, S., Belhaïne, A., Rosier, A., & Guillin, O. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000955 · Cited by 34
Zickgraf, H. F., & Mayes, S. D. (2018) · Journal of Developmental and Physical Disabilities · doi:10.1007/s10882-018-9645-6 · Cited by 33
“Although potential side effects are a decrease in appetite for stimulants (Cortese et al. 2012) and weight gain for antipsychotics (McCracken et al. 2002; Nagaraj et al. 2006; Pandina et al. 2007), neither type of medication was associated with atypical eating behaviors.”
BackgroundInfluentialCharman, T. (2008) · Psychiatry · doi:10.1016/j.mppsy.2008.05.015 · Cited by 41
Jangro, W. C., Preval, H., Southard, R., Klotz, S. G., & Francis, A. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-9 · Cited by 29
The QT interval and psychotropic medications in children: Recommendations for clinicians
McNally, P., McNicholas, F., & Oslizlok, P. C. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0573-0 · Cited by 32
“In addition to their use for the treatment of psychoses in children, antipsychotic drugs are increasingly being used for nonpsychotic disorders such as autism, ADHD, mood disorders, aggressive behaviour, acute behavioural dyscontrol and disruptive behaviours [4, 26, 53, 65, 82, 109, 111, 118, 134].”
BackgroundHealthcare issues for children on the autism spectrum
Volkmar, F. R., Wiesner, L. A., & Westphal, A. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000228754.64743.66 · Cited by 29
Self-citationPsychoactive drug prescribing by Dutch child and adolescent psychiatrists
Hugtenburg, J. G., Heerdink, E. R., & Tso, Y. H. (2005) · Acta Paediatrica · doi:10.1080/08035250510036840 · Cited by 29
Psychopharmacologic Management of Serious Behavioral Disturbance in ASD
Stigler, K. A. (2013) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2013.07.005 · Cited by 29
Development of mavoglurant and its potential for the treatment of fragile X syndrome
Gomez‐Mancilla, B., Berry‐Kravis, E., Hagerman, R. J., von Raison, F., Apostol, G., Ufer, M., Gasparini, F., & Jacquemont, S. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.857400 · Cited by 33
“The ABC-C and its subscales have been used as outcome measures in pivotal clinical trials of treatments for autism and ADHD [42-45], and because of the considerable overlap between symptoms in these disorders and FXS, the ABC-C was a rational choice to use in FXS clinical studies.”
InfluentialThe STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome
Bird, L. M., Ochoa‐Lubinoff, C., Tan, W., Heimer, G., Melmed, R. D., Rakhit, A., Visootsak, J., During, M. J., Holcroft, C., Burdine, R. D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011409 · Cited by 29
Thom, R. P., Pereira, J. A., Sipsock, D., & McDougle, C. J. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01292-2 · Cited by 28
Self-citationKoevoet, D., Deschamps, P. K. H., & Kenemans, J. L. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1078586 · Cited by 33
Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date
Fung, L. K., & Hardan, A. Y. (2015) · CNS Drugs · doi:10.1007/s40263-015-0252-0 · Cited by 29
Joshi, G., Biederman, J., Wozniak, J. R., Doyle, R., Hammerness, P. G., Galdo, M., Sullivan, N., Williams, C., Brethel-Haurwitz, K. M., Woodworth, K. Y., et al. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00219.x · Cited by 33
“Importantly, none of the BPD participants with ASD experienced EPS, which is consistent with low rates of EPS similar to placebo reported with risperidone therapy in youth with autistic disorder with marked irritability/aggression [37].”
ResultLongitudinal trajectories of aberrant behavior in fragile X syndrome
Hustyi, K. M., Hall, S. S., Jo, B., Lightbody, A. A., & Reiss, A. L. (2014) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.07.003 · Cited by 32
“…1985) has garnered much attention for its potential sensitivity in measuring treatment response and detecting changes in behavior (cf., Aman, 2012; McCracken et al., 2002; Research Units on Pediatric Psychopharmacology Autism Network, 2005; Schroeder, Rojahn, & Reese, 1997; Shedlack, Hennen,…”
BackgroundValdovinos, M. G., Nelson, S. M., Kuhle, J. L., & Dierks, A. M. (2009) · Journal of Mental Health Research in Intellectual Disabilities · doi:10.1080/19315860903104807 · Cited by 28
Unwin, G., & Deb, S. S. (2010) · Advances in Mental Health and Intellectual Disabilities · doi:10.5042/amhid.2010.0538 · Cited by 30
Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders
Pandina, G., Bilder, R. M., Harvey, P. D., Keefe, R. S. E., Aman, M. G., & Gharabawi, G. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.036 · Cited by 30
Self-citationAggression, Tantrums, and Other Externally Driven Challenging Behaviors
Singh, N. N., Lancioni, G. E., Winton, A. S. W., & Singh, J. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8065-6_26 · Cited by 39
Jahangard, L., Akbarian, S., Haghighi, M., Ahmadpanah, M., Keshavarzi, A., Bajoghli, H., Bahmani, D. S., Holsboer‐Trachsler, E., & Brand, S. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.12.010 · Cited by 34
“…symptoms in bipolar disorder (Diaz-Caneja et al. , 2014), irritability associated with pervasive developmental disorder (Barnard et al. , 2002, McCracken et al. , 2002), psychiatric symptoms of tic disorders and obsessive-compulsive disorders (Bachmann et al. , 2015), and irritability in…”
Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis
van Schalkwyk, G. I., Lewis, A. S., Beyer, C., Johnson, J. A., van Rensburg, S. H., & Bloch, M. H. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1371012 · Cited by 30
Autism: a large unmet medical need and a complex research problem
Gerlai, J., & Gerlai, R. T. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00165-3 · Cited by 35
“Risperidone has been investigated the most in recent studies and it has been found to treat moderate to severe behavior problems that are associated with autism [61].”
BackgroundAttention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, and Conduct Disorder
Althoff, R. R., Rettew, D. C., & Hudziak, J. J. (2003) · Psychiatric Annals · doi:10.3928/0048-5713-20030401-05 · Cited by 33
Psychopharmacology of Autism Spectrum Disorder
Siegel, M. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.006 · Cited by 27
Choi, K. Y. K., & Kovshoff, H. (2013) · Research in Autism · doi:10.1016/j.rasd.2013.04.010 · Cited by 33
“Also, as disruptive behaviour can create particular challenges for parents (Birkin et al., 2004; McCracken et al., 2002; Shea et al., 2004; West & Waldrop, 2006), interventions are very likely to be required to address this”
BackgroundMethodInfluentialPsychopharmacology of autism spectrum disorders: A selective review
Mohiuddin, S. S., & Ghaziuddin, M. (2012) · Autism · doi:10.1177/1362361312453776 · Cited by 35
“McCracken et al. (2002), as part of the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, conducted a double-blind placebo-controlled study to determine the efficacy and safety of risperidone in children with autism and behavioral symptoms such as irritability, hyperactivity,…”
MethodInvestigational drugs in early-stage clinical trials for autism spectrum disorder
Hong, M. P., & Erickson, C. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1649656 · Cited by 27
Aggressive Behaviour in Adults with Intellectual Disability
Oliver-Africano, P., Murphy, D., & Tyrer, P. (2009) · CNS Drugs · doi:10.2165/11310930-000000000-00000 · Cited by 27
Lit, L., Sharp, F. R., Bertoglio, K., Stamova, B., Ander, B. P., Sossong, A. D., & Hendren, R. L. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.23 · Cited by 26
“…of ASD such as social reciprocity 7 , and few studies show clearly improved adaptive functioning 2 , double blind, placebo controlled studies have demonstrated the effectiveness of the atypical antipsychotic risperidone in reducing irritability and aggression symptoms in children with autism 8–10 .”
Pugliese, C. E., Fritz, M. S., & White, S. W. (2014) · Autism · doi:10.1177/1362361314548731 · Cited by 34
“Among children with ASD, aggression has been cited as a frequent problem (Farmer and Aman, 2011; McCracken et al., 2002; Storch et al., 2012), and evidence indicates that, similar to neurotypical samples (e.g. Kashdan et al., 2009), social anxiety and facets of aggression co-occur (Farrugia and…”
BackgroundScheifes, A., Stolker, J. J., Egberts, T. C. G., Nijman, H. L. I., & Heerdink, E. R. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01353.x · Cited by 32
Gonzalez–Heydrich, J., Pandina, G., Fleisher, C., Hsin, O., Raches, D., Bourgeois, B. F. D., & Biederman, J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649075 · Cited by 27
Review of antipsychotics in children and adolescents
Kapetanovic, S., & Simpson, G. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.14.1871 · Cited by 33
“[62] followed 48 responders from the short-term study [39] for 6 – 8 months, and found significant improvement in communication, daily living skills and socialisation measured by the Vineland Adaptive Behavior Scales.”
BackgroundMethodInfluentialLindsay, R. L., Leone, S., & Aman, M. G. (2004) · Clinical Pediatrics · doi:10.1177/000992280404300504 · Cited by 27
Self-citationThe role of pharmacists in primary care
Ballantyne, P. J. (2007) · BMJ · doi:10.1136/bmj.39213.660394.80 · Cited by 31
Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder
Handen, B. L., Taylor, J., & Tumuluru, R. (2011) · ijamh · doi:10.1515/ijamh.2011.039 · Cited by 26
“In a 2002 New England Journal of Medicine paper, the Research Units on Pediatric Psychopharmacology in Autism reported the results of a multicenter, placebo-controlled, double-blind trial of risperidone for irritability in ASD (32) .”
BackgroundMartin, H., Choi, J. E., Rodrigues, A. R., & Eshel, N. (2024) · JAACAP Open · doi:10.1016/j.jaacop.2024.01.010 · Cited by 33
“47,48 Short-term ( 6 months) treatment with these medications can improve irritability and aggression scores in children and adolescents with ASD.”
Hellings, J. A., Cardona, A., & Schroeder, S. R. (2010) · Journal of Mental Health Research in Intellectual Disabilities · doi:10.1080/19315864.2010.494763 · Cited by 28
on behalf of the ISACA guideline working group, D’Alò, G. L., Crescenzo, F. D., Amato, L., Cruciani, F., Davoli, M., Fulceri, F., Minozzi, S., Mitrova, Z., Morgano, G. P., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02956-8 · Cited by 22
Moyal, W. N., Lord, C., & Walkup, J. T. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0050-4 · Cited by 28
Wink, L. K., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0154 · Cited by 27
Self-citationCognitive control of feature bindings: evidence from children with autistic spectrum disorder
Zmigrod, S., de Sonneville, L. M. J., Colzato, L. S., Swaab, H., & Hommel, B. (2011) · Psychological Research · doi:10.1007/s00426-011-0399-3 · Cited by 28
“(a dopamine-receptor antagonist; McCracken et al., 2002).”
BackgroundGünther, T., Herpertz‐Dahlmann, B., JOLLES, J., & Konrad, K. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.725 · Cited by 29
“…disorders like schizophrenia (Grcevich et al. 1996; Ar-menteros et al. 1997), bipolar disorder developmental disorder (Barnard et al. 2002; McCracken et al. 2002; King et al. 2003), tic disorders and obsessive-compulsive disorder (Sc-ahill et al. 2003; Gilbert et al. 2004), and disruptive…”
Improving the Prediction of Response to Therapy in Autism
Bent, S., & Hendren, R. L. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.011 · Cited by 25
Treatment of Psychopathology in People with Intellectual and other Disabilities
Sturmey, P. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205701003 · Cited by 34
Autism Research: An Objective Quantitative Review of Progress and Focus Between 1994 and 2015
Whyatt, C. P., & Torres, E. B. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01526 · Cited by 27
Ceranoglu, T. A., Cassano, P., Hoskova, B., Green, A., Dallenbach, N. T., DiSalvo, M., Biederman, J., & Joshi, G. (2021) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2020.4986 · Cited by 31
Chez, M. G., Kile, S. J., Lepage, C., Parise, C. A., Benabides, B., & Hankins, A. I. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3703-x · Cited by 25
Group PCIT for Preschoolers with Autism Spectrum Disorder and Externalizing Behavior Problems
Ros, R., & Graziano, P. A. (2019) · Journal of Child and Family Studies · doi:10.1007/s10826-019-01358-z · Cited by 31
Thom, R. P., McDougle, C. J., & Hazen, E. P. (2019) · Psychosomatics · doi:10.1016/j.psym.2019.04.003 · Cited by 33
Self-citationPharmacotherapy in Autism and Related Disorders.
Handen, B. L., & Lubetsky, M. J. (2005) · School Psychology Quarterly · doi:10.1521/scpq.20.2.155.66514 · Cited by 28
Characterization of Potential Outcome Measures for Future Clinical Trials in Fragile X Syndrome
Berry‐Kravis, E., Sumis, A. M., Kim, O.-K., Lara, R., & Wuu, J. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0564-8 · Cited by 28
“challenge in clinical trials involving testing of subjects with autism as well and has limited cognitive assessment in the large controlled trial of risperidone in autistic subjects (McCracken et al. 2002).”
BackgroundSokolski, K. N., Chicz-DeMet, A., & DeMet, E. M. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454604773840599 · Cited by 27
“…8 weeks, although the incidence of abnormal movements in this study was not significantly different from that noted in patients receiving placebo, and weekly assessments with the Abnormal Involuntary Movement Scale and Simpson-Angus Scale indicated no EPS in either group (McCracken et al. 2002).”
Are We There Yet? The Clinical Potential of Intranasal Oxytocin in Psychiatry
C. J. Liu, J., A. McErlean, R., & R. Dadds, M. (2012) · Current Psychiatry Reviews · doi:10.2174/157340012798994902 · Cited by 24
“, for risperidone [37]).”
Views of Teachers on Anxiety Symptoms in Students with Autism Spectrum Disorder
Syriopoulou–Delli, C. K., Polychronopoulou, S. A., Kolaitis, G. A., & Antoniou, A.-S. G. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3752-1 · Cited by 34
Vanwong, N., Ngamsamut, N., Nuntamool, N., Hongkaew, Y., Sukprasong, R., Puangpetch, A., Limsila, P., & Sukasem, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565074 · Cited by 29
“Our results also support a previous study that demonstrated risperidone was related to an average weight gain in children compared with placebo (McCracken et al., 2002).”
ResultBeversdorf, D. Q., Ferguson, B. J., Hunter, S., Hirst, K., Lolli, B., Bellesheim, K. R., Barton, A. U., Muckerman, J. E., Takahashi, N., Selders, K. J., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06452-1 · Cited by 29
“…of symptoms associated with ASD have predominantly targeted associated co-occurring psychiatric symptoms, such as the use of antipsychotic medications to target irritability and agitation (McCracken et al. 2002; Shea et al. 2004; Myers and Johnson 2007; Owen et al 2009; Marcus et al 2009).”
Stereotypy, Self-Injury, and Related Abnormal Repetitive Behaviors
Bodfish, J. W. (2007) · Springer eBooks · doi:10.1007/0-387-32931-5_25 · Cited by 29
Bastiaens, L. (2008) · Community Mental Health Journal · doi:10.1007/s10597-008-9154-7 · Cited by 26
“…research data base on the use of atypical antipsychotics in children and adolescents is still sparse: most of the randomized, controlled trials have only been done with Risperidone and in patients with developmental disabilities (McCracken et al. 2002; Snyder et al. 2002; Buitelaar et al. 2001).”
BackgroundDiagnoses and Antipsychotic Treatment Among Youths in a Public Mental Health System
Patel, N. C., Crismon, M. L., & Shafer, A. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g203 · Cited by 24
Vanwong, N., Prommas, S., Puangpetch, A., Hongkaew, Y., Nuntamool, N., Nakorn, C. N., Ngamsamut, N., Limsila, P., & Sukasem, C. (2016) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22009 · Cited by 24
Pennap, D. D., ZITO, J. M., Santosh, P., Tom, S. E., Onukwugha, E., & Magder, L. S. (2018) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2018.0240 · Cited by 26
Risperidone use in the treatment of behavioral symptoms in children with autism.
West, L., & Waldrop, J. B. (2006) · PubMed · Cited by 24
Pharmacological treatment of pathologic aggression in children
Barzman, D. H., & Findling, R. (2008) · International Review of Psychiatry · doi:10.1080/09540260801887819 · Cited by 28
Potegal, M., Carlson, G. A., Margulies, D. M., Basile, J., Gutkovich, Z. A., & Wall, M. M. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0020-2 · Cited by 27
Genetics of Childhood Disorders: XLIV. Autism, Part 3: Psychopharmacology of Autism
McDougle, C. J., & Posey, D. J. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200211000-00021 · Cited by 24
Self-citationRisperidone-Associated Diabetes Mellitus in Children
Koller, E. A., Cross, J. T., & Schneider, B. (2004) · PEDIATRICS · doi:10.1542/peds.113.2.421 · Cited by 24
Atypical antipsychotics for autism spectrum disorder: a network meta-analysis
Meza, N., Franco, J. V. A., Sguassero, Y., Núñez, V., Liquitay, C. M. E., Rees, R., Williams, K. J., Rojas, V., Rojas, F., Pringsheim, T. M., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014965.pub2 · Cited by 40
Vo, L. C., Snyder, C. S., McCracken, C. M., McDougle, C. J., McCracken, J. T., Aman, M. G., Tierney, E., Arnold, L. E., Levi, D. S., Kelleman, M. S., et al. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0090 · Cited by 24
Self-citationKalvin, C. B., Gladstone, T. R., Jordan, R. P., Rowley, S., Marsh, C. L., Ibrahim, K., & Sukhodolsky, D. G. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-020-04627-9 · Cited by 26
Staben, J., Koch, M., Reid, K., Muckerheide, J., Gilman, L., McGuinness, F., Kiesser, S., Oswald, I. W. H., Koby, K. A., Martin, T. J., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1185737 · Cited by 29
“The rates of symptom improvement reported in these studies are consistent with traditional prescription medications used in ASD therapy (McCracken et al., 2002; Marcus et al., 2009; Nadeau et al., 2011; Rossignol and Frye, 2014; Sturman et al., 2017), highlighting the potential of a cannabis-based treatment approach a…”
ResultMedication Use and Spending Trends Among Children With ADHD in Florida's Medicaid Program, 1996–2005
Fullerton, C. A., Epstein, A. M., Frank, R. G., Normand, S. T., Fu, C. X., & McGuire, T. G. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201100095 · Cited by 24
Dinca, O., Paul, M., & Spencer, N. J. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056541 · Cited by 24
“Six studies fulfilled the inclusion criteria for the review (two papers described the same trial) (McCracken et al., 2002; McDougle, Holmes et al., 1998; Vegso, 1995; McDougle, Volkmar et al., 1996; Buchsbaum et al., 2001; Dollfus et al., 1992; Malone et al., 2001).”
Ercan, E. S., Başay, B. K., Başay, Ö., Durak, S. F., & Özbaran, B. (2011) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-5-10 · Cited by 26
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.